retatrutide phase 2 nejm 2023 weight loss percent 48 weeks Results: 24% in Early trial data for retatrutide

Assuming it follows similar patterns, retatrutide most likely wont be recommended for people with : A history of pancreatitis Thyroid cancer or multiple endocrine neoplasia syndrome Severe kidney problems Severe liver issues Worried about side effects

replace daily

Gastrointestinal side effects like constipation on semaglutide or constipation on tirzepatide can be harder to manage on a lighter frame

Preparation Phase (Both Products): Remove the pen from refrigeration 15-30 minutes before injection to allow it to reach room temperature, which reduces injection discomfort Wash hands thoroughly with soap and water Check the medication label to confirm correct drug, dose, and expiration date Inspect the solutionit should be clear and colorless

The 4 mg arm landed near the territory that semaglutide occupies, the 8 mg arm matched what tirzepatide achieves at its top dose, and the 12 mg arm went somewhere no single or dual agonist had reached in a trial of that size